Ensysce Biosciences Q4 net loss narrows to $2.8 mln

Ensysce Biosciences

30/03/2026 22:02

Overview

US clinical-stage pharma reported Q4 net loss narrowed to $2.8 mln

In 2025, company advanced PF614 to Phase 3 trial and PF614-MPAR under FDA Breakthrough Therapy

Q4 R&D expenses fell slightly

Outlook

Company expects continued losses as R&D efforts toward regulatory approvals progress

Ensysce advancing PF614 toward regulatory submission and potential commercialization

Company pursuing accelerated development and market entry for PF614-MPAR with FDA support

Result Drivers

CLINICAL ADVANCEMENT - Increased external R&D costs in 2025, driven by PF614 and PF614-MPAR clinical and pre-clinical programs

GRANT FUNDING - Federal grant funding rose in Q4, supporting research activities for OUD and MPAR programs

Company press release: ID:nACSYV2NNa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Income
-$2.8 mln


Analyst Coverage

Wall Street's median 12-month price target for Ensysce Biosciences Inc is $25.23, about 4,682% above its March 27 closing price of $0.53

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)